UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 118

Sortiert nach

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

Journal of clinical oncology, 2021-07, Vol.39 (20), p.JCO2003488-2303

2021

Link zum Volltext

Verfügbarkeit prüfen

Use of Prednisone With Abiraterone Acetate in Metastatic Castration‐Resistant Prostate Cancer

The oncologist (Dayton, Ohio), 2014-12, Vol.19 (12), p.1231-1240

2014

Link zum Volltext

Verfügbarkeit prüfen

Population-based study of disease trajectory after radical treatment for high-risk prostate cancer

BJU international, 2024-04

2024

Link zum Volltext

Verfügbarkeit prüfen

Mathematical modeling of bone marrow – peripheral blood dynamics in the disease state based on current emerging paradigms, part II

Journal of theoretical biology, 2019-01, Vol.460, p.37-55

2019

Link zum Volltext

Verfügbarkeit prüfen

Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN

European urology, 2022-02, Vol.81 (2), p.184-192

2022

Link zum Volltext

Verfügbarkeit prüfen

A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients

World journal of urology, 2023-12, Vol.41 (12), p.3535-3542

2023

Link zum Volltext

Verfügbarkeit prüfen

Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors

Frontiers in oncology, 2020-08, Vol.10, p.1349-1349

2020

Link zum Volltext

Verfügbarkeit prüfen

Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study

European journal of cancer (1990), 2023-11, Vol.193, p.113290-113290, Article 113290

2023

Link zum Volltext

Verfügbarkeit prüfen

Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

British journal of cancer, 2024-01, Vol.130 (1), p.73-81

2024

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study

Japanese journal of clinical oncology, 2020-07, Vol.50 (7), p.810-820

2020

Link zum Volltext

Verfügbarkeit prüfen

Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide

Prostate cancer and prostatic diseases, 2023-12, Vol.26 (4), p.813-813

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study

International journal of urology, 2022-06, Vol.29 (6), p.533-540

2022

Link zum Volltext

Verfügbarkeit prüfen

Mathematical modeling of bone marrow – peripheral blood dynamics in the disease state based on current emerging paradigms, part I

Mathematical biosciences, 2016-04, Vol.274, p.83-93

2016

Link zum Volltext

Verfügbarkeit prüfen

Targeting cyclin D1 for high risk myelodysplastic syndromes

Leukemia research, 2012-08, Vol.36 (8), p.964-965

Mundle, Suneel D

2012

Link zum Volltext

Verfügbarkeit prüfen

Transient therapy-related surge in serum tumor biomarkers: Characterizing behavior and postulating its biologic role

Critical reviews in oncology/hematology, 2013-04, Vol.86 (1), p.15-22

2013

Link zum Volltext

Verfügbarkeit prüfen

Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis

Annals of hematology, 2008-07, Vol.87 (7), p.527-536

2008

Link zum Volltext

Verfügbarkeit prüfen

Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial

Asian journal of andrology, 2023-11, Vol.25 (6), p.653-661

2023

Link zum Volltext

Verfügbarkeit prüfen

Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial

Asian journal of andrology, 2022-03, Vol.24 (2), p.161-166

2022

Link zum Volltext

Verfügbarkeit prüfen

Evolving intricacies and implications of E2F1 regulation

The FASEB journal, 2003-04, Vol.17 (6), p.569-574

2003

Link zum Volltext

Verfügbarkeit prüfen

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

The lancet oncology, 2019-05, Vol.20 (5), p.686-700

2019

Link zum Volltext

Verfügbarkeit prüfen

Advances in erythropoietic growth factor therapy for myelodysplastic syndromes

Expert opinion on biological therapy, 2006-11, Vol.6 (11), p.1099-1104

Mundle, Suneel D

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 118

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(114)
Mit Volltextzugriff
(112)

Publikationsform

Artikel
(117)
Buchkapitel
(1)

Sprache

Englisch
(118)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(56)
Science & Technology
(56)
Humans
(55)
Male
(32)
Apoptosis
(28)
Hematology
(27)
Oncology
(23)
Biological And Medical Sciences
(22)
Myelodysplastic Syndromes - Pathology
(22)
Medical Sciences
(21)
Female
(19)
Aged
(18)
Hematologic And Hematopoietic Diseases
(17)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(17)
Myelodysplastic Syndromes
(16)
Middle Aged
(14)
Adult
(10)
Bone Marrow - Pathology
(10)
Prostate Cancer
(9)
Bone Marrow Cells - Pathology
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

Use of Prednisone With Abiraterone Acetate in Metastatic Castration‐Resistant Prostate Cancer

Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study

Population-based study of disease trajectory after radical treatment for high-risk prostate cancer

Mathematical modeling of bone marrow – peripheral blood dynamics in the disease state based on current emerging paradigms, part II

Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN

A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients

Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors

Prostate-specific Membrane Antigen Positron Emission Tomography–detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study

Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study

Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study

Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide

Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study

Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study

Mathematical modeling of bone marrow – peripheral blood dynamics in the disease state based on current emerging paradigms, part I

Targeting cyclin D1 for high risk myelodysplastic syndromes

Transient therapy-related surge in serum tumor biomarkers: Characterizing behavior and postulating its biologic role

Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis

Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial

Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial

Evolving intricacies and implications of E2F1 regulation

Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

Advances in erythropoietic growth factor therapy for myelodysplastic syndromes

Suchergebnisse filtern